Egetis Therapeutics publishes prospectus for admission to trading of shares, in the private placement, on Nasdaq Stockholm
October 11, 2023
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR OTHER MEASURES.
Stockholm, October 11, 2023. On October 10, 2023 Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) announced that the Company had secured a combined financing of approximately SEK 462 million comprising a private placement (the “Private Placement”) and a debt financing.
A prospectus has been prepared due to the Private Placement and has today, October 11, 2023, been approved and registered by the SFSA and is available on the Company’s website, www.egetis.com.
Bryan, Garnier & Co acted as Sole Global Coordinator & Sole Bookrunner and Advokatfirman Vinge KB acted as Legal Adviser.